Daniel B Reeves

List of Publications by Year
in descending order

52 papers	1,488 citations	393982 19 h-index	360668 35 g-index
71 all docs	71 docs citations	71 times ranked	2682 citing authors

#	Article	IF	Citations
1	HIV reservoir quantification using cross-subtype multiplex ddPCR. IScience, 2022, 25, 103615.	1.9	16
2	Evolution during primary HIV infection does not require adaptive immune selection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	3
3	Improving vaccination coverage and offering vaccine to all school-age children allowed uninterrupted in-person schooling in King County, WA: Modeling analysis. Mathematical Biosciences and Engineering, 2022, 19, 5699-5716.	1.0	2
4	Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Computational Biology, 2022, 18, e1010003.	1.5	8
5	Multi-scale modelling reveals that early super-spreader events are a likely contributor to novel variant predominance. Journal of the Royal Society Interface, 2022, 19, 20210811.	1.5	16
6	Widespread testing, case isolation and contact tracing may allow safe school reopening with continued moderate physical distancing: A modeling analysis of King County, WA data. Infectious Disease Modelling, 2021, 6, 24-35.	1.2	29
7	Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation. ELife, 2021, 10, .	2.8	9
8	Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events. ELife, 2021, 10, .	2.8	142
9	Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions. AIDS Reviews, 2021, 23, 28-39.	0.5	4
10	A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. Cell Reports Medicine, 2021, 2, 100243.	3.3	44
11	Rapid vaccination and partial lockdown minimize 4th waves from emerging highly contagious SARS-CoV-2 variants. Med, 2021, 2, 573-574.	2.2	7
12	Slight reduction in SARS-CoV-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation. Scientific Reports, 2021, 11, 11838.	1.6	17
13	Timing HIV infection with a simple and accurate population viral dynamics model. Journal of the Royal Society Interface, 2021, 18, 20210314.	1.5	8
14	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Scientific Reports, 2021, 11, 15531.	1.6	70
15	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. Viruses, 2021, 13, 1921.	1.5	10
16	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	2.1	25
17	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23652-23662.	3.3	193
18	Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand. PLoS Pathogens, 2020, 16, e1008179.	2.1	24

#	Article	IF	Citations
19	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. PLoS Computational Biology, 2020, 16, e1007626.	1.5	20
20	Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women. PLoS Pathogens, 2020, 16, e1008286.	2.1	41
21	Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy. Journal of Clinical Investigation, 2020, 130, 3543-3559.	3.9	69
22	Title is missing!. , 2020, 16, e1007626.		0
23	Title is missing!. , 2020, 16, e1007626.		0
24	Title is missing!. , 2020, 16, e1007626.		0
25	Title is missing!. , 2020, 16, e1007626.		0
26	Model-based estimation of superinfection prevalence from limited datasets. Journal of the Royal Society Interface, 2018, 15, 20170968.	1.5	1
27	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2116-2127.	1.4	17
28	A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nature Communications, 2018, 9, 4811.	5.8	96
29	Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. BMC Biology, 2018, 16, 75.	1.7	29
30	Autologous Stem Cell Transplantation Disrupts Adaptive Immune Responses during Rebound Simian/Human Immunodeficiency Virus Viremia. Journal of Virology, 2017, 91, .	1.5	15
31	Nonlinear Nonequilibrium Simulations of Magnetic Nanoparticles. , 2017, , 121-156.		1
32	Anti-proliferative therapy for HIV cure: a compound interest approach. Scientific Reports, 2017, 7, 4011.	1.6	35
33	Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. PLoS Medicine, 2017, 14, e1002475.	3.9	22
34	Latent Cell Proliferation Sustains the HIV Reservoir on Long-term ART—A Mathematical Modeling Study with Implications for Cure. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
35	Generalized Scaling and the Master Variable for Brownian Magnetic Nanoparticle Dynamics. PLoS ONE, 2016, 11, e0150856.	1.1	2
36	Mixed Brownian alignment and Néel rotations in superparamagnetic iron oxide nanoparticle suspensions driven by an ac field. Physical Review B, 2015, 92, .	1.1	109

#	Article	IF	Citations
37	Comparisons of characteristic timescales and approximate models for Brownian magnetic nanoparticle rotations. Journal of Applied Physics, 2015, 117, 233905.	1.1	13
38	Combined Néel and Brown rotational Langevin dynamics in magnetic particle imaging, sensing, and therapy. Applied Physics Letters, 2015, 107, 223106.	1.5	36
39	Toward Localized <italic>In Vivo</italic> Biomarker Concentration Measurements. IEEE Transactions on Magnetics, 2015, 51, 1-4.	1.2	37
40	Approaches for Modeling Magnetic Nanoparticle Dynamics. Critical Reviews in Biomedical Engineering, 2014, 42, 85-93.	0.5	38
41	Measuring the microenvironmental temperature around magnetic nanoparticles. Materials Research Society Symposia Proceedings, 2014, 1625, 1.	0.1	0
42	Nonlinear simulations to optimize magnetic nanoparticle hyperthermia. Applied Physics Letters, 2014, 104, 102403.	1.5	23
43	Magnetic nanoparticle sensing: decoupling the magnetization from the excitation field. Journal Physics D: Applied Physics, 2014, 47, 045002.	1.3	24
44	Langevin equation simulation of Brownian magnetic nanoparticles with experimental and model comparisons. , 2013, , .		1
45	Molecular sensing with magnetic nanoparticles using magnetic spectroscopy of nanoparticle Brownian motion. Biosensors and Bioelectronics, 2013, 50, 441-446.	5.3	74
46	Temperature measurements using static field magnetic particle spectroscopy. , 2013, , .		1
47	In vivo measurement of local biomarker concentrations. , 2013, , .		1
48	Quantification of magnetic nanoparticles with low frequency magnetic fields: compensating for relaxation effects. Nanotechnology, 2013, 24, 325502.	1.3	18
49	TH-A-WAB-01: Biomarker Sensing. Medical Physics, 2013, 40, 519-519.	1.6	0
50	Simulations of magnetic nanoparticle Brownian motion. Journal of Applied Physics, 2012, 112, 124311.	1.1	46
51	TU-G-217A-07: Magnetic Nanoparticle Quantitation: Compensating for Relaxation Effects. Medical Physics, 2012, 39, 3927-3927.	1.6	3
52	SUâ€Eâ€Iâ€81: Toward in Vivo Magnetic Spectroscopy of Brownian Motion. Medical Physics, 2012, 39, 3643-3643.	1.6	1